MacKay James W, Aboelmagd Sharief, Gaffney J Karl
Department of Radiology, Norfolk & Norwich University Hospital, Norwich, UK,
Clin Rheumatol. 2015 Sep;34(9):1633-8. doi: 10.1007/s10067-015-2936-8. Epub 2015 Apr 19.
Magnetic resonance (MR) imaging-based disease activity scores (DAS) in axial spondyloarthritis (axSpA) are rarely employed in the normal clinical setting, whereas clinical DAS are used routinely to monitor disease activity and set thresholds for biologic treatment. The objectives of this study were to evaluate the correlation between MR and clinical DAS in a general axSpA outpatient population and to assess the difference in MR DAS in individuals with high and low clinical DAS. This was a prospective, cross-sectional observational study. Forty participants with axSpA who presented for MR of the whole spine and sacroiliac joints as part of ongoing management were included. Completion of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) was performed at the time of MR examination. MR images were scored by two independent observers using the Spondyloarthritis Research Consortium of Canada (SPARCC) MR DAS. There were weak, non-significant correlations between total SPARCC score and BASDAI (r = 0.18, p = 0.26), ASDAS using erythrocyte sedimentation rate (ASDAS-ESR) (r = 0.31, p = 0.07) and ASDAS using C-reactive protein level (ASDAS-CRP) (r = 0.31, p = 0.05). There was no significant difference in the SPARCC score of participants with high and low clinical DAS. MR DAS may provide information about disease activity not provided by the current standard of clinical DAS and may be considered as a useful adjunct in clinical practice.
基于磁共振成像(MR)的轴向脊柱关节炎(axSpA)疾病活动评分(DAS)在常规临床环境中很少使用,而临床DAS则常规用于监测疾病活动并设定生物治疗阈值。本研究的目的是评估普通axSpA门诊患者中MR与临床DAS之间的相关性,并评估临床DAS高和低的个体在MR DAS方面的差异。这是一项前瞻性横断面观察研究。纳入了40名因正在进行的管理而接受全脊柱和骶髂关节MR检查的axSpA患者。在MR检查时完成巴斯强直性脊柱炎疾病活动指数(BASDAI)和强直性脊柱炎疾病活动评分(ASDAS)。MR图像由两名独立观察者使用加拿大脊柱关节炎研究联盟(SPARCC)MR DAS进行评分。总SPARCC评分与BASDAI(r = 0.18,p = 0.26)、使用红细胞沉降率的ASDAS(ASDAS-ESR)(r = 0.31,p = 0.07)和使用C反应蛋白水平的ASDAS(ASDAS-CRP)(r = 0.31,p = 0.05)之间存在微弱的、无统计学意义的相关性。临床DAS高和低的参与者的SPARCC评分没有显著差异。MR DAS可能提供当前临床DAS标准未提供的疾病活动信息,可被视为临床实践中的有用辅助手段。